Osteoarthritis drugs in development

Researchers are working to better understand what causes osteoarthritis and how its signs and symptoms can be relieved. There's still no cure. But new drugs are being developed. One day they may help relieve osteoarthritis pain and halt the joint damage caused by the disease.

Though many drugs are available for osteoarthritis, many cause side effects. Nonsteroidal anti-inflammatory drugs (NSAIDs), for example, carry a risk of stomach bleeding. Scientists continue to look for new medications that effectively relieve the pain of osteoarthritis without causing new problems. Research into new treatments for osteoarthritis falls into several areas:

New drugs for pain relief:

Researchers looking into new drugs for relief of pain and inflammation associated with osteoarthritis are searching for options that offer fewer side effects, including:
- LOX/COX inhibitors. These drugs block the cyclooxygenase (COX) enzyme that's involved in joint inflammation, much like NSAIDs do. But LOX/COX inhibitors also block the lipoxygenase (LOX) enzyme, reducing the risk of gastrointestinal side effects, such as stomach bleeding. These drugs may prove to be as effective as and safer than COX-2 inhibitors and traditional NSAIDs.
- Topical NSAIDs. Putting traditional NSAIDs into a cream to be applied to your skin could mean less damage to your gastrointestinal tract. Small short-term studies have found some benefit to topical NSAIDs.


Antibiotics

Antibiotics are traditionally used to fight infections. It's now known that antibiotics can also decrease inflammation. Osteoarthritis isn't believed to be caused by infection, but researchers hope antibiotics will work to reduce the joint swelling that's common in osteoarthritis. Tests on animals showed that antibiotics had some benefit. Researchers are now experimenting with antibiotic therapy in people who have osteoarthritis.

Modifying cartilage

The cartilage that protects your joints and allows them to move smoothly can be damaged by osteoarthritis. Researchers hope that altering the makeup of your cartilage might stop the damage or prevent it from occurring. Researchers are examining two ways of altering the cartilage in your joints:

Injections.
Injecting a gel and liquid compound into the joint — a process called visco-supplementation — might protect the joint by cushioning it and allowing it to move more freely. The process has been approved for use in people with osteoarthritis of the knee and is being researched for use in other joints. Visco-supplementation is usually reserved for people for whom other pain relief methods haven't worked.

Supplements.
Researchers have found two substances that play a role in joint repair and protection. Glucosamine sulfate and chondroitin sulfate — available over-the-counter as dietary supplements — have both shown some benefit in clinical trials, though the reliability of some studies has been questioned. Both glucosamine and chondroitin occur naturally in cartilage. Supplementing your own cartilage with artificially made substances could offer some joint protection, but more research is needed. The National Institutes of Health is conducting trials.


Gene therapy

Researchers hope that targeting certain genes in your body might influence cells in your joints to reduce inflammation and joint damage. One way to do this might be to block the action of damaging genes. Another way might be to replace the damaging genes with genes that would reverse joint damage. One roadblock to gene therapy is finding a way to deliver the genes to the body. Gene therapy for osteoarthritis is still in the very early stages, though some animal research has shown promise.


Drug development and approval:

Long waits, no guarantees

It takes many years to develop new drugs. Beyond proving they work, researchers must prove they're safe for people to use. It's encouraging to look ahead to treatments that may one day make treating osteoarthritis safer and more efficient. But know that some of these experimental drugs could take years to win approval and others may never make it to the market. In the meantime, talk with your doctor about what you can do to make the most of the treatments available to you now.

You can check the pharmaceutical pipeline of Bulresearch

http://www.chartsbank.com/PipelineList.aspx

to find out which current therapies are being developed

Unblocking the drugs pipeline

The pharmaceutical industry needs a shot in the arm. Where will that innovation come from?

FOR an industry that prides itself on innovation, the words came as a damning indictment and an embarrassing truth: "In many cases, developers have no choice but to use the tools and concepts of the last century to assess this century's candidates." So wrote the US Food and Drug Administration (FDA) in a 2004 report on the pipeline problem ­ the slowdown in the emergence of new drugs despite significant scientific advances and increasing amounts of money being pumped into research. The US regulatory agency pointed the finger at the archaic practices of the US drug discovery and development industry, and its reluctance to take up new technologies.
Yet many pharmaceutical companies were already aware of the problem, and are charting bold new courses in an effort to reduce drug failure rates and bring more treatments to market. The industry leaders pioneering the next generation of tools and practices are fighting their corner.

Bulresearch offers best in class pharmaceutical pipeline database:

http://www.chartsbank.com/PipelineList.aspx

Drug pipeline problem

http://www.chartsbank.com/PipelineList.aspx

Market analysts estimate that most pharmaceutical firms will need to double the number of new chemical entities they develop to meet Wall Street analysts’ growth expectations. Pharmaceutical-biotechnology alliances will shore up pipelines of pharmaceutical companies, reported by business intelligence firm Bulresearch Inc.

Called the pipeline problem, pharmaceutical companies are partly victims of their industry’s success. Rapid growth of blockbuster products forces each major company to build a stronger pipeline of new blockbusters. Pharmaceutical-biotechnology alliances help solve the pipeline problem that plagues pharmaceutical companies. These partnerships are a new competitive ground for more blockbusters than can be developed internally.

The pharmaceutical pipeline is filled with promise

Doctors are close to adding one more powerful ingredient to their antiviral recipe against AIDS, Miraviroc Researchers at Pfizer have developed the first in a new class of compounds that would prevent HIV from entering or infecting a healthy cell. So far, the medications that have saved millions of AIDS patients around the world have thwarted HIV at the end of its reproductive cycle; Pfiezer's compound, a once a day pill called Miraviroc, targets the beginning of the disease process. Now in the last stage of being tested in patients, the compound, in combination with other anti-HIV drugs, could become a significant roadblock in preventing HIV infections from mushrooming into full-blown cases of AIDS.

http://www.chartsbank.com/PipelineList.aspx

Therapeutic Classification

Most pipeline directories identify the uses of a drug with a combination of codes and keyword indexing. Codes make retrieval of related compounds easier by introducing a hierarchical scheme.
For example, if all products being investigated for cardiovascular applications are classified under codes beginning with the letter "C," users do not need to key in the variety of terms that could be assigned by indexers to describe heart medications, such as "antiarrhythmics," cardiostimulants," "coronary vasodilators," "antihypertensives," etc.
In the lessons that follow, we will look at the therapeutic classification scheme used in each of the major pipeline databases.

http://www.chartsbank.com/PipelineList.aspx

uses also the ATC system

Regards

Drug pipeline

In the pharmaceutical sector a drugs pipeline consists of the drugs that a company has under development or is testing. This includes completely new drugs, variants of existing drugs and new applications of existing drugs.
The pipeline starts with new drugs discoveries and it is important to asses companies’ ability to discover new drugs as well as drugs that are currently in the pipeline - the early stage (start) of the pipline needs to be refileld as drugs move up
New drugs require extensive development, pre-clincal testing, three stages of clinical testings and then have to approved in each country the company wishes to sell the drug in.
It is not uncommon for companies to buy and sell drugs that are in various stages of development, or to enter into agreements to jointly develop or market drugs. In these circumstances one company may receive milestone payments from another for completing particular stages of development, trials and approval as well as royalties on the drug once it is marketed.
Although larger pharmaceutical companies always ahve pipelines with many drugs in them, which may appear to spread the risk, it is often the case that most of the value of the pipeline lies in a small number of drugs - or even in a single “blockbuster” drug
Assessing the pipeline is often the most important part of valuing a company and the most difficult. Companies largely dependent on established products are easier to assess, and there are fewer uncertainties in the valuation. The best growth opportunities in the sector are small companies with a plaform for developing new drugs which are of course very uncertain.

Exactly this is what we have here:

http://www.chartsbank.com/PipelineList.aspx

Drug R&D Process Overview

If you want to use the pharmaceutical pipelen of Bulresearch

http://www.chartsbank.com/PipelineList.aspx

Please read the common information that follows

Many thousands of chemical substances are investigated each year for their possible benefits in alleviating human and animal diseases. Many organizations, such as companies, universities, and government agencies, are involved in drug research and development.
As you work with drug information you will often hear about the "R&D pipeline" or the "drug pipeline." This term refers to the progress of a drug/compound from the point it is discovered in the laboratory to its launch in the marketplace, if successful.
Every compound investigated for pharmaceutical potential must undergo rigorous testing as prescribed by government regulations. It is estimated that up to 5,000 compounds may be investigated for every one that ultimately makes it to the market as a pharmaceutical. In the United States, drug evaluation and testing is overseen by the Food & Drug Administration (FDA).
Organizations seeking drug approval in the United States must file two major regulatory documents with the FDA.
The first is submitted after pre-clinical or animal studies are completed in order to begin testing on humans. The formal name for this document is a Notice of Claimed Investigational Exemption for a New Drug, and is commonly referred to as an Investigational New Drug Application or IND. In the United States, human testing is done in three to four separately-evaluated steps or "phases."
After successful completion of testing on humans, final approval is sought from the FDA. The second major document filed is the New Drug Application, commonly referred to as the NDA. This document is filed to obtain approval to market the product.

Pharmaceutical pipeline

Referring to our online pharmaceutical pipeline database
http://www.chartsbank.com/PipelineList.aspx

we were also engaged by a major pharmaceutical company to perform a full portfolio assessment of their product pipeline and help the company pursue potential licensing agreements in order to realize its 5 to 10 year earnings aspirations.

Phase 1:
The first step was to quickly identify the most attractive and available compounds, or drugs in development, that would be good candidates for developing the portfolio. Working closely with the client, Bulresearch team scanned a vast library of pipeline compounds, fully assessing the profitability of various therapeutic areas and disease states, trends in populations, unmet medical need, and strategic fit. The team also tapped not only the client's knowledge and experience but also that of Bulresearch and external experts worldwide. As a result of this intensive analysis, the team quickly narrowed 1,200 potential leads to 18 priority compounds, and finally, to 6 viable licensing candidates.

Phase 2:
Bulresearch team then helped the client pursue these deals. We worked with the client to develop a clear assessment plan for meeting with licensing candidates and coached the client through multiple rounds of negotiations. By helping the client maintain focus, momentum, and objectivity, the Bulresearch team provided both tactical and strategic support.

Phase 3:
As a final phase to this engagement, the Bulresearch team provided additional insights beyond the central objective by working with the client to identify potential revenue gaps and establish strategic priorities. Further, it helped define performance improvements required to boost sales and set specific operating targets to help the client track outcomes.

pharmaceutical sales force

We added additional case studies to our pharmaceutical sales force case studies on our www.chartsbank.com



These are

Sigma Company - Improving sales force performance - case study. The document provides information about the current situation, objectives, key questions, approach. Real company, real numbers. 548 words, 3 pages.

ICN Pharmaceuticals - Convincing Physicians Through Consumer Demand - case study. The document provides information about the current situation, objectives, strategy, key questions, approach, implementation. Real company, real numbers. 639 words, 2 pages

the category can be reached directly

http://www.chartsbank.com/DiagramCategory.aspx?CategoryID=42

Regards

drug pipeline

I want to mention that the drug pipeline of Bulresearch has an unique feature to differentiate from all other drug pipeline databases and this is that the drug pipeline on www.chartsbank.com shows not only which substance drug or ICN in which phase is, but also whether this is the beginning or the end of that phase.

We continue to do weekly updates

There are no preclinical projects in our database, when we say over 3000 that means they all start from phase I.

The drug pipeline could be accessed directly from

http://www.chartsbank.com/PipelineList.aspx

Regards

pharmaceutical marketing

Detailing was, is and will stay the most powerful tool to market drugs. There are interesting issues surrounding the pharmaceutical sales force and the classification and targeting of physicians. There are a lot of case studies and I would recommend a site where you can actually learn from the case studies with real companies and real numbers

http://www.chartsbank.com/
just check the sales force case studies category

There are all kind of issues
Sales Manager Training
Sales Force restructuring
Non Performer /Pool territory
Managing Performer Non-performer
Managing Unionised Field Force

http://www.chartsbank.com/DiagramCategory.aspx?CategoryID=42

Regards
Bulresearch

pharmaceutical pipeline

Drug pipeline is one of the most attractive titles in the industry. Everybody is looking for a complete and cheap source of data. The trick is you can get the whole pipeline for Glaxo or Pfizer but you cannot get the whole data for let's say diabetes. First you must search which companies do something in the area and then look for their drugs in development.

http://www.chartsbank.com/PipelineList.aspx

is a database with over 3 000 records of drugs in development of more than 600 companies. And guess what - you can have a subscription for half an hour that costs only 20 USD and 30 minutes is more than enough to find what you are looking for. So there is no necessity to pay lets say 500 USD for monthly subscription.

In the pipeline

I want to thank to all our clients that already use or used http://www.chartsbank.com/PipelineList.aspx

Nice to have you on board!

I just want to remind that the pharmaceutical pipeline by www.chartbank.com constist of more than 30 data fields for more than 3000 projects in development of more than 600 companies. Recently we add also the formulation category.

In our guest view, you can already check which companies are included. Almost every week we add additional companies.